Edmund M Qiao1,2, Julie A Lynch3, Kyung M Lee3, Nikhil V Kotha1,2, Vinit Nalawade1,2, Rohith S Voora1,2, Alexander S Qian2, Tyler J Nelson1,2, Kosj Yamoah4, Isla P Garraway5, Tyler F Stewart6, J Kellogg Parsons7, Brent S Rose1,2. 1. Veterans Affairs San Diego Health Care System, La Jolla, San Diego, CA, USA. 2. Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, San Diego, CA, USA. 3. Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, USA. 4. Department of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. 5. Department of Urology, University of California Los Angeles, Los Angeles, CA, USA. 6. Division of Hematology-Oncology, Department of Internal Medicine, University of California San Diego, La Jolla, CA, USA. 7. Department of Urology, University of California San Diego, La Jolla, San Diego, CA, USA.
Abstract
BACKGROUND: Despite higher risks associated with prostate cancer, young African American men are poorly represented in prostate-specific antigen (PSA) trials, which limits proper evidence-based guidance. We evaluated the impact of PSA screening, alongside primary care provider utilization, on prostate cancer outcomes for these patients. METHODS: We identified African American men aged 40-55 years, diagnosed with prostate cancer between 2004 and 2017 within the Veterans Health Administration. Inverse probability of treatment-weighted propensity scores were used in multivariable models to assess PSA screening on PSA levels higher than 20, Gleason score of 8 or higher, and metastatic disease at diagnosis. Lead-time adjusted Fine-Gray regression evaluated PSA screening on prostate cancer-specific mortality (PCSM), with noncancer death as competing events. All statistical tests were 2-sided. RESULTS: The cohort included 4726 patients. Mean age was 51.8 years, with 84-month median follow-up. There were 1057 (22.4%) with no PSA screening prior to diagnosis. Compared with no screening, PSA screening was associated with statistically significantly reduced odds of PSA levels higher than 20 (odds ratio [OR] = 0.56, 95% confidence interval [CI] = 0.49 to 0.63; P < .001), Gleason score of 8 or higher (OR = 0.78, 95% CI = 0.69 to 0.88; P < .001), and metastatic disease at diagnosis (OR = 0.50, 95% CI = 0.39 to 0.64; P < .001), and decreased PCSM (subdistribution hazard ratio = 0.52, 95% CI = 0.36 to 0.76; P < .001). Primary care provider visits displayed similar effects. CONCLUSIONS: Among young African American men diagnosed with prostate cancer, PSA screening was associated with statistically significantly lower risk of PSA levels higher than 20, Gleason score of 8 or higher, and metastatic disease at diagnosis and statistically significantly reduced risk of PCSM. However, the retrospective design limits precise estimation of screening effects. Prospective studies are needed to validate these findings.
BACKGROUND: Despite higher risks associated with prostate cancer, young African American men are poorly represented in prostate-specific antigen (PSA) trials, which limits proper evidence-based guidance. We evaluated the impact of PSA screening, alongside primary care provider utilization, on prostate cancer outcomes for these patients. METHODS: We identified African American men aged 40-55 years, diagnosed with prostate cancer between 2004 and 2017 within the Veterans Health Administration. Inverse probability of treatment-weighted propensity scores were used in multivariable models to assess PSA screening on PSA levels higher than 20, Gleason score of 8 or higher, and metastatic disease at diagnosis. Lead-time adjusted Fine-Gray regression evaluated PSA screening on prostate cancer-specific mortality (PCSM), with noncancer death as competing events. All statistical tests were 2-sided. RESULTS: The cohort included 4726 patients. Mean age was 51.8 years, with 84-month median follow-up. There were 1057 (22.4%) with no PSA screening prior to diagnosis. Compared with no screening, PSA screening was associated with statistically significantly reduced odds of PSA levels higher than 20 (odds ratio [OR] = 0.56, 95% confidence interval [CI] = 0.49 to 0.63; P < .001), Gleason score of 8 or higher (OR = 0.78, 95% CI = 0.69 to 0.88; P < .001), and metastatic disease at diagnosis (OR = 0.50, 95% CI = 0.39 to 0.64; P < .001), and decreased PCSM (subdistribution hazard ratio = 0.52, 95% CI = 0.36 to 0.76; P < .001). Primary care provider visits displayed similar effects. CONCLUSIONS: Among young African American men diagnosed with prostate cancer, PSA screening was associated with statistically significantly lower risk of PSA levels higher than 20, Gleason score of 8 or higher, and metastatic disease at diagnosis and statistically significantly reduced risk of PCSM. However, the retrospective design limits precise estimation of screening effects. Prospective studies are needed to validate these findings.
Authors: Suzanne van Meer; Robert A de Man; Minneke J Coenraad; Dave Sprengers; Karin M J van Nieuwkerk; Heinz-Josef Klümpen; Peter L M Jansen; Jan N M IJzermans; Martijn G H van Oijen; Peter D Siersema; Karel J van Erpecum Journal: J Hepatol Date: 2015-06-20 Impact factor: 25.083
Authors: Carol E DeSantis; Kimberly D Miller; Ann Goding Sauer; Ahmedin Jemal; Rebecca L Siegel Journal: CA Cancer J Clin Date: 2019-02-14 Impact factor: 508.702
Authors: Anjali S Advani; Benjamin Atkeson; Carrie L Brown; Bercedis L Peterson; Laura Fish; Jeffrey L Johnson; Jon P Gockerman; Marc Gautier Journal: Cancer Date: 2003-03-15 Impact factor: 6.860
Authors: Stephen W Duffy; Iris D Nagtegaal; Matthew Wallis; Fay H Cafferty; Nehmat Houssami; Jane Warwick; Prue C Allgood; Olive Kearins; Nancy Tappenden; Emma O'Sullivan; Gill Lawrence Journal: Am J Epidemiol Date: 2008-05-25 Impact factor: 4.897
Authors: Karthik Rao; Stella Liang; Michael Cardamone; Corinne E Joshu; Kyle Marmen; Nrupen Bhavsar; William G Nelson; H Ballentine Carter; Michael C Albert; Elizabeth A Platz; Craig E Pollack Journal: BMC Urol Date: 2018-05-09 Impact factor: 2.264
Authors: Edmund M Qiao; Rohith S Voora; Vinit Nalawade; Nikhil V Kotha; Alexander S Qian; Tyler J Nelson; Michael Durkin; Lucas K Vitzthum; James D Murphy; Tyler F Stewart; Brent S Rose Journal: Cancer Med Date: 2021-09-16 Impact factor: 4.452